A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC.

NCT07064863 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

31

Enrollment

OTHER

Sponsor class

Conditions

NMIBC
Non-Muscle Invasive Bladder Urothelial Carcinoma
Bladder (Urothelial, Transitional Cell) Cancer
Urothelial Carcinoma Bladder

Interventions

DRUG: Gemcitabine + BCG
DRUG: BCG (TICE strain)

Sponsor

Queen's University

Collaborators

[object Object]